From: Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas
 | N | Fibulin-4 low (−/+) | Fibulin-4 high (++/+++) | X 2 | P | ||
---|---|---|---|---|---|---|---|
 | n | % | n | % |  |  | |
Normal | 40 | 37 | 92.5% | 3 | 7.5% | 65.455 | <0.01 |
Benign | 60 | 40 | 66.7% | 20 | 33.3% | Â | Â |
Pathology type | Â | Â | Â | Â | Â | 0.141 | 0.932 |
Serous cystadenoma | 25 | 16 | 64% | 9 | 36% | Â | Â |
Mucinous cystadenoma | 22 | 15 | 68.2% | 7 | 31.8% | Â | Â |
Endometrioid tumor | 13 | 9 | 69.2% | 4 | 30.8% | Â | Â |
Carcinoma | 160 | 45 | 28.1% | 115 | 71.9% | Â | Â |
Pathology type | Â | Â | Â | Â | Â | 0.736 | 0.692 |
Serous cystadenocarcinoma | 58 | 16 | 27.6% | 42 | 72.4% | Â | Â |
Mucinous cystadenocarcinoma | 56 | 14 | 25% | 42 | 75% | Â | Â |
Endometrioid carcinoma | 46 | 15 | 32.6% | 31 | 67.4% | Â | Â |
Cell differentiation | Â | Â | Â | Â | Â | 32.987 | <0.01 |
High and Medium | 88 | 41 | 46.6% | 47 | 53.4% | Â | Â |
Low | 72 | 4 | 5.6% | 68 | 94.4% | Â | Â |
Tumor stage | Â | Â | Â | Â | Â | 21.629 | <0.01 |
Low stage | 74 | 34 | 45.9% | 40 | 54.1% | Â | Â |
High stage | 86 | 11 | 12.8% | 75 | 87.2% | Â | Â |
Nodal status | Â | Â | Â | Â | Â | 35.752 | <0.01 |
Positive | 83 | 8 | 9.6% | 75 | 90.4% | Â | Â |
Negative | 77 | 41 | 53.2% | 36 | 46.8% | Â | Â |